Zhenzhen Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhenzhen Chen has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Pingping Zhu
School of Life Sciences, Zhengzhou University, Zhengzhou, China
10 shared publicationsZimai Liu
School of Life Sciences, Zhengzhou University, Zhengzhou, China
8 shared publicationsXiaoxi Wang
School of Life Sciences Zhengzhou University Zhengzhou Henan China
7 shared publicationsXueqin Zhu
School of Life Sciences Zhengzhou University Zhengzhou 450001 China
7 shared publicationsKai Li
School of Life Sciences, Zhengzhou University, Zhengzhou, China
6 shared publications- Pingping Zhu
School of Life Sciences, Zhengzhou University, Zhengzhou, China
6 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Fusion exosomes improve the antitumor effect of sorafenib by reversing tumor cell stemness
- 1 October 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Open AccessFusion exosomes improve the antitumor effect of sorafenib by reversing tumor cell stemness
- Open Access
- 9 May 2026
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (5) , e70292
In Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy
Cancer stem cells (CSCs) characterized by the capacity of self‐renewal and drug resistance, are a major cause of tumour recurrence and metastasis. However, CSCs are mainly localized in the deep and hypoxic regions of the tumour microenvironment that hinder drug penetration. Furthermore, their overexpression of the CD24/Siglec10 immune checkpoint axis markedly suppresses immune clearance, severely limiting the efficacy of current therapeutic strategies. To address this challenge, this study developed an in situ engineered “cascade‐amplified” drug‐loaded vesicle delivery system, aiming to achieve deep drug delivery into CSC‐enriched regions and enhance anti‐tumour immune responses. Based on a biomimetic “core‐shell” nanoplatform (siXkr8/Dox@PMLC), this system initiates a cascade within the TME where Doxorubicin (Dox) induces tumour cells to generate drug‐loaded apoptotic bodies (ApoBDs). These ApoBDs serve as primary vesicles that, upon uptake by adjacent tumour cells, trigger secondary apoptosis, establishing a “cascade‐amplified” cycle of enhanced drug delivery. Meanwhile, the silencing of the phospholipid scramblase Xkr8 via siRNA inhibits phosphatidylserine (PS) exposure on the surface of ApoBDs, thereby preventing their recognition and clearance by M2‐type macrophages and facilitating immune phenotype remodelling. Furthermore, through targeted blockade of the CD24/Siglec‐10 immune axis, the nanoplatform enhances macrophage‐mediated phagocytosis of CSCs. In summary, this strategy achieves deep eradication of CSCs and synergistically enhances anti‐tumour immunotherapy, demonstrating significant translational potential.
- 9 May 2026
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (5) , e70292
Open AccessIn Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy
Cancer stem cells (CSCs) characterized by the capacity of self‐renewal and drug resistance, are a major cause of tumour recurrence and metastasis. However, CSCs are mainly localized in the deep and hypoxic regions of the tumour microenvironment that hinder drug penetration. Furthermore, their overexpression of the CD24/Siglec10 immune checkpoint axis markedly suppresses immune clearance, severely limiting the efficacy of current therapeutic strategies. To address this challenge, this study developed an in situ engineered “cascade‐amplified” drug‐loaded vesicle delivery system, aiming to achieve deep drug delivery into CSC‐enriched regions and enhance anti‐tumour immune responses. Based on a biomimetic “core‐shell” nanoplatform (siXkr8/Dox@PMLC), this system initiates a cascade within the TME where Doxorubicin (Dox) induces tumour cells to generate drug‐loaded apoptotic bodies (ApoBDs). These ApoBDs serve as primary vesicles that, upon uptake by adjacent tumour cells, trigger secondary apoptosis, establishing a “cascade‐amplified” cycle of enhanced drug delivery. Meanwhile, the silencing of the phospholipid scramblase Xkr8 via siRNA inhibits phosphatidylserine (PS) exposure on the surface of ApoBDs, thereby preventing their recognition and clearance by M2‐type macrophages and facilitating immune phenotype remodelling. Furthermore, through targeted blockade of the CD24/Siglec‐10 immune axis, the nanoplatform enhances macrophage‐mediated phagocytosis of CSCs. In summary, this strategy achieves deep eradication of CSCs and synergistically enhances anti‐tumour immunotherapy, demonstrating significant translational potential.
- Open Access
- 3 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (4) , e08632
In Situ Engineering of Tumor Cells as Self‐Sustaining cDC1 Programming Factories for Effective Cancer Immunotherapy
Conventional type 1 dendritic cells (cDC1s) play a crucial role in initiating and regulating antitumor immunity. However, the insufficient infiltration and dysfunctional state of these cells within the tumor microenvironment hinder antitumor immune response. A tumor‐derived extracellular vesicle (EV), termed AS16‐EL@MPLA/p‐FX, is designed to engineer tumor cells into cDC1 programming factories. The EV lumen carries a plasmid encoding XCL1 and FLT3L. Leveraging the prolonged circulation time and homotypic targeting properties of tumor‐derived EV, AS16‐EL@MPLA/p‐FX demonstrates enhanced tumor‐selective accumulation and efficient cellular internalization. Following uptake, tumor cells are reprogrammed into in situ cytokine factories that continuously secrete XCL1 and FLT3L, which effectively recruit and differentiate cDC1s within the tumor microenvironment. Simultaneously, MPLA embedded in the EV membrane is released locally and activates the newly accumulated cDC1s through the TLR4 pathway. Furthermore, an AS16 peptide is tethered to the EV surface via a matrix metalloproteinase‐2–cleavable linker. The enzymatic release of AS16 disrupts the VEGF–NRP1 interaction, preventing cDC1 exhaustion. The engineered EV, AS16‐EL@MPLA/p‐FX, exhibited remarkable tumor‐targeting capabilities, promoting the recruitment, differentiation, and activation of cDC1s. This innovative approach not only significantly inhibited tumor growth but also triggered a robust immune memory response, safeguarding against tumor metastasis and recurrence.
- 3 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (4) , e08632
Open AccessIn Situ Engineering of Tumor Cells as Self‐Sustaining cDC1 Programming Factories for Effective Cancer Immunotherapy
Conventional type 1 dendritic cells (cDC1s) play a crucial role in initiating and regulating antitumor immunity. However, the insufficient infiltration and dysfunctional state of these cells within the tumor microenvironment hinder antitumor immune response. A tumor‐derived extracellular vesicle (EV), termed AS16‐EL@MPLA/p‐FX, is designed to engineer tumor cells into cDC1 programming factories. The EV lumen carries a plasmid encoding XCL1 and FLT3L. Leveraging the prolonged circulation time and homotypic targeting properties of tumor‐derived EV, AS16‐EL@MPLA/p‐FX demonstrates enhanced tumor‐selective accumulation and efficient cellular internalization. Following uptake, tumor cells are reprogrammed into in situ cytokine factories that continuously secrete XCL1 and FLT3L, which effectively recruit and differentiate cDC1s within the tumor microenvironment. Simultaneously, MPLA embedded in the EV membrane is released locally and activates the newly accumulated cDC1s through the TLR4 pathway. Furthermore, an AS16 peptide is tethered to the EV surface via a matrix metalloproteinase‐2–cleavable linker. The enzymatic release of AS16 disrupts the VEGF–NRP1 interaction, preventing cDC1 exhaustion. The engineered EV, AS16‐EL@MPLA/p‐FX, exhibited remarkable tumor‐targeting capabilities, promoting the recruitment, differentiation, and activation of cDC1s. This innovative approach not only significantly inhibited tumor growth but also triggered a robust immune memory response, safeguarding against tumor metastasis and recurrence.
- Open Access
- 25 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (33) , e07317
Bioprinted Organoids: An Innovative Engine in Biomedicine
Bioprinted organoids integrate bioprinting technology with organoid research, enabling the simultaneous reconstruction of human tissue morphology and physiological function in vitro. This approach offers distinct advantages in organoid fabrication, particularly in terms of structural precision, tissue mimicry, and functional fidelity. By leveraging the complementary strengths of both technologies, bioprinted organoids allow for the fabrication of personalized, architecturally engineered models that more accurately replicate organogenesis, physiological processes, and disease progression. Herein, this review outlines the key advantages of bioprinted organoids, with a focus on their ability to precisely control morphology, dimensions, and spatial organization. Bioprinted organoids are further categorized into three types based on their cellular origins and summarize recent progress in their application for human tissue modeling. Finally, ongoing challenges and future possibilities are sketched out, offering insights for potential innovation and research directions in the field. Bioprinted organoids not only propel the advancement of organoid research but also drive the evolution of bioprinting technologies. This integrated approach represents a powerful synergy between biomanufacturing and clinical medicine to pave the way for a new era in biomedical science and personalized healthcare.
- 25 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (33) , e07317
Open AccessBioprinted Organoids: An Innovative Engine in Biomedicine
Bioprinted organoids integrate bioprinting technology with organoid research, enabling the simultaneous reconstruction of human tissue morphology and physiological function in vitro. This approach offers distinct advantages in organoid fabrication, particularly in terms of structural precision, tissue mimicry, and functional fidelity. By leveraging the complementary strengths of both technologies, bioprinted organoids allow for the fabrication of personalized, architecturally engineered models that more accurately replicate organogenesis, physiological processes, and disease progression. Herein, this review outlines the key advantages of bioprinted organoids, with a focus on their ability to precisely control morphology, dimensions, and spatial organization. Bioprinted organoids are further categorized into three types based on their cellular origins and summarize recent progress in their application for human tissue modeling. Finally, ongoing challenges and future possibilities are sketched out, offering insights for potential innovation and research directions in the field. Bioprinted organoids not only propel the advancement of organoid research but also drive the evolution of bioprinting technologies. This integrated approach represents a powerful synergy between biomanufacturing and clinical medicine to pave the way for a new era in biomedical science and personalized healthcare.
- 5 July 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 385, 114001
Enhancing antigen presentation in cancer stem cells via peptide-based nanoparticles for effective immunotherapy
- 5 July 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 385, 114001
Enhancing antigen presentation in cancer stem cells via peptide-based nanoparticles for effective immunotherapy
- 2 July 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (27) , 24938-24953
Engineered Bacteria-Nanoparticle Conjugate Reprograms Immunosuppressive Niche via Dendritic Cell-Centric Innate-Adaptive Immune Coupling
The immunosuppressive tumor microenvironment (TME) represents a critical barrier to effective T cell activation, contributing to immunotherapy resistance. Dendritic cells (DCs), essential initiators of T cell-mediated adaptive immunity, frequently display both quantitative defects and functional impairments within the TME. Compounding this challenge, emerging evidence highlights the indispensable role of innate immunity in sustaining T cell activity and establishing durable immunological memory. To address these limitations, we engineered M-CHNP/D: a bacteria-nanoparticle hybrid platform integrating Escherichia coli with acid-responsive calcium carbonate nanoparticles encapsulating the programmed cell death ligand-1 blocking peptide DPPA-1. Leveraging the motility and targeting capabilities of bacteria, M-CHNP/D achieves a deep tumor penetration and neutralizes the acidic TME. M-CHNP/D induced tumor-cell-derived CCL3 upregulation, driving DC recruitment and spatial redistribution within the tumor parenchyma. This intervention enhanced DCs' antigen-presenting capacity, ultimately potentiating adaptive immune responses. Furthermore, M-CHNP/D administration significantly increased the population of innate immune cells and induced their phenotypic reprogramming toward antitumor functional states. By reshaping the immune "hot" network, M-CHNP/D combined with radiotherapy effectively inhibited tumor growth and recurrence. M-CHNP/D demonstrates significant potential in modulating both innate and adaptive immunity, offering a robust strategy for improving cancer immunotherapy outcomes.
- 2 July 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (27) , 24938-24953
Engineered Bacteria-Nanoparticle Conjugate Reprograms Immunosuppressive Niche via Dendritic Cell-Centric Innate-Adaptive Immune Coupling
The immunosuppressive tumor microenvironment (TME) represents a critical barrier to effective T cell activation, contributing to immunotherapy resistance. Dendritic cells (DCs), essential initiators of T cell-mediated adaptive immunity, frequently display both quantitative defects and functional impairments within the TME. Compounding this challenge, emerging evidence highlights the indispensable role of innate immunity in sustaining T cell activity and establishing durable immunological memory. To address these limitations, we engineered M-CHNP/D: a bacteria-nanoparticle hybrid platform integrating Escherichia coli with acid-responsive calcium carbonate nanoparticles encapsulating the programmed cell death ligand-1 blocking peptide DPPA-1. Leveraging the motility and targeting capabilities of bacteria, M-CHNP/D achieves a deep tumor penetration and neutralizes the acidic TME. M-CHNP/D induced tumor-cell-derived CCL3 upregulation, driving DC recruitment and spatial redistribution within the tumor parenchyma. This intervention enhanced DCs' antigen-presenting capacity, ultimately potentiating adaptive immune responses. Furthermore, M-CHNP/D administration significantly increased the population of innate immune cells and induced their phenotypic reprogramming toward antitumor functional states. By reshaping the immune "hot" network, M-CHNP/D combined with radiotherapy effectively inhibited tumor growth and recurrence. M-CHNP/D demonstrates significant potential in modulating both innate and adaptive immunity, offering a robust strategy for improving cancer immunotherapy outcomes.
- Open Access
- 27 March 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-16
CAR-T therapy dilemma and innovative design strategies for next generation
Chimeric antigen receptor (CAR)-T-cell therapy has shown remarkable curative effects on hematological tumors, driving the exponential growth in CAR-T-related research. Although CD19-targeting CAR-T-cell therapy has displayed remarkable promise in clinical trials, many obstacles are arising that limit its therapeutic efficacy in tumor immunotherapy. The “dilemma” of CAR-T cell-based tumor therapy includes lethal cytotoxicity, restricted trafficking, limited tumor infiltration, an immunosuppressive microenvironment, immune resistance and limited potency. The solution to CAR-T-cell therapy’s dilemma requires interdisciplinary strategies, including synthetic biology-based ON/OFF switch, bioinstructive scaffolds, nanomaterials, oncolytic viruses, CRISPR screening, intestinal microbiota and its metabolites. In this review, we will introduce and summarize these interdisciplinary-based innovative technologies for the next generation CAR-T-cell design and delivery to overcome the key barriers of current CAR-T cells.
- 27 March 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-16
Open AccessCAR-T therapy dilemma and innovative design strategies for next generation
Chimeric antigen receptor (CAR)-T-cell therapy has shown remarkable curative effects on hematological tumors, driving the exponential growth in CAR-T-related research. Although CD19-targeting CAR-T-cell therapy has displayed remarkable promise in clinical trials, many obstacles are arising that limit its therapeutic efficacy in tumor immunotherapy. The “dilemma” of CAR-T cell-based tumor therapy includes lethal cytotoxicity, restricted trafficking, limited tumor infiltration, an immunosuppressive microenvironment, immune resistance and limited potency. The solution to CAR-T-cell therapy’s dilemma requires interdisciplinary strategies, including synthetic biology-based ON/OFF switch, bioinstructive scaffolds, nanomaterials, oncolytic viruses, CRISPR screening, intestinal microbiota and its metabolites. In this review, we will introduce and summarize these interdisciplinary-based innovative technologies for the next generation CAR-T-cell design and delivery to overcome the key barriers of current CAR-T cells.
- Open Access
- 18 December 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (12) , 1-12
CPNE7 promotes colorectal tumorigenesis by interacting with NONO to initiate ZFP42 transcription
Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related death globally. Also, there is still a lack of effective therapeutic strategies for CRC patients owing to a poor understanding of its pathogenesis. Here, we analysed differentially expressed genes in CRC and identified CPNE7 as a novel driver of colorectal tumorigenesis. CPNE7 is highly expressed in CRC and negatively correlated with patients’ prognosis. Upregulation of CPNE7 promotes proliferation and metastasis of cancer cells in vitro and in vivo, and vice versa. Mechanistically, CPNE7 interacts with NONO to initiate ZFP42 transcription, thus promoting CRC progression. Moreover, ZFP42 knockdown inhibits tumor cell proliferation and migration while promoting apoptosis. Notably, delivery of CPNE7 shRNA or the small molecule gramicidin, which blocks the interaction between CPNE7 and NONO, hinders tumor growth in vivo. In conclusion, our findings demonstrate that the CPNE7-NONO-ZFP42 axis promotes colorectal tumorigenesis and may be a new potential therapeutic target.
- 18 December 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (12) , 1-12
Open AccessCPNE7 promotes colorectal tumorigenesis by interacting with NONO to initiate ZFP42 transcription
Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related death globally. Also, there is still a lack of effective therapeutic strategies for CRC patients owing to a poor understanding of its pathogenesis. Here, we analysed differentially expressed genes in CRC and identified CPNE7 as a novel driver of colorectal tumorigenesis. CPNE7 is highly expressed in CRC and negatively correlated with patients’ prognosis. Upregulation of CPNE7 promotes proliferation and metastasis of cancer cells in vitro and in vivo, and vice versa. Mechanistically, CPNE7 interacts with NONO to initiate ZFP42 transcription, thus promoting CRC progression. Moreover, ZFP42 knockdown inhibits tumor cell proliferation and migration while promoting apoptosis. Notably, delivery of CPNE7 shRNA or the small molecule gramicidin, which blocks the interaction between CPNE7 and NONO, hinders tumor growth in vivo. In conclusion, our findings demonstrate that the CPNE7-NONO-ZFP42 axis promotes colorectal tumorigenesis and may be a new potential therapeutic target.
- 20 February 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (9) , 6946-6962
Logic “AND Gate Circuit”-Based Gasdermin Protein Expressing Nanoplatform Induces Tumor-Specific Pyroptosis to Enhance Cancer Immunotherapy
Pyroptosis mediated by gasdermin protein has shown great potential in cancer immunotherapies. However, the low expression of gasdermin proteins and the systemic toxicity of nonspecific pyroptosis limit its clinical application. Here, we designed a synthetic biology strategy to construct a tumor-specific pyroptosis-inducing nanoplatform M-CNP/Mn@pPHS, in which a pyroptosis-inducing plasmid (pPHS) was loaded onto a manganese (Mn)-doped calcium carbonate nanoparticle and wrapped in a tumor-derived cell membrane. M-CNP/Mn@pPHS showed an efficient tumor targeting ability. After its internalization by tumor cells, the degradation of M-CNP/Mn@pPHS in the acidic endosomal environment allowed the efficient endosomal escape of plasmid pPHS. To trigger tumor-specific pyroptosis, pPHS was designed according to the logic "AND gate circuit" strategy, with Hif-1α and Sox4 as two input signals and gasdermin D induced pyroptosis as output signal. Only in cells with high expression of Hif-1α and Sox4 simultaneously will the output signal gasdermin D be expressed. Since Hif-1α and Sox4 are both specifically expressed in tumor cells, M-CNP/Mn@pPHS induces the tumor-specific expression of gasdermin D and thus pyroptosis, triggering an efficient immune response with little systemic toxicity. The Mn2+ released from the nanoplatform further enhanced the antitumor immune response by stimulating the cGAS-STING pathway. Thus, M-CNP/Mn@pPHS efficiently inhibited tumor growth with 79.8% tumor regression in vivo. We demonstrate that this logic "AND gate circuit"-based gasdermin nanoplatform is a promising strategy for inducing tumor-specific pyroptosis with little systemic toxicity.
- 20 February 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (9) , 6946-6962
Logic “AND Gate Circuit”-Based Gasdermin Protein Expressing Nanoplatform Induces Tumor-Specific Pyroptosis to Enhance Cancer Immunotherapy
Pyroptosis mediated by gasdermin protein has shown great potential in cancer immunotherapies. However, the low expression of gasdermin proteins and the systemic toxicity of nonspecific pyroptosis limit its clinical application. Here, we designed a synthetic biology strategy to construct a tumor-specific pyroptosis-inducing nanoplatform M-CNP/Mn@pPHS, in which a pyroptosis-inducing plasmid (pPHS) was loaded onto a manganese (Mn)-doped calcium carbonate nanoparticle and wrapped in a tumor-derived cell membrane. M-CNP/Mn@pPHS showed an efficient tumor targeting ability. After its internalization by tumor cells, the degradation of M-CNP/Mn@pPHS in the acidic endosomal environment allowed the efficient endosomal escape of plasmid pPHS. To trigger tumor-specific pyroptosis, pPHS was designed according to the logic "AND gate circuit" strategy, with Hif-1α and Sox4 as two input signals and gasdermin D induced pyroptosis as output signal. Only in cells with high expression of Hif-1α and Sox4 simultaneously will the output signal gasdermin D be expressed. Since Hif-1α and Sox4 are both specifically expressed in tumor cells, M-CNP/Mn@pPHS induces the tumor-specific expression of gasdermin D and thus pyroptosis, triggering an efficient immune response with little systemic toxicity. The Mn2+ released from the nanoplatform further enhanced the antitumor immune response by stimulating the cGAS-STING pathway. Thus, M-CNP/Mn@pPHS efficiently inhibited tumor growth with 79.8% tumor regression in vivo. We demonstrate that this logic "AND gate circuit"-based gasdermin nanoplatform is a promising strategy for inducing tumor-specific pyroptosis with little systemic toxicity.
- 25 January 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 367, 61-75
Biomimetic-gasdermin-protein-expressing nanoplatform mediates tumor-specific pyroptosis for cancer immunotherapy
- 25 January 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 367, 61-75
Biomimetic-gasdermin-protein-expressing nanoplatform mediates tumor-specific pyroptosis for cancer immunotherapy